Consolidated Portfolio Review Corp Novartis Ag Transaction History
Consolidated Portfolio Review Corp
- $723 Billion
- Q2 2025
A detailed history of Consolidated Portfolio Review Corp transactions in Novartis Ag stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 2,629 shares of NVS stock, worth $339,509. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,629
Previous 2,598
1.19%
Holding current value
$339,509
Previous $290 Million
9.84%
% of portfolio
0.04%
Previous 0.05%
Shares
5 transactions
Others Institutions Holding NVS
# of Institutions
1,583Shares Held
136MCall Options Held
1.72MPut Options Held
1.7M-
Dodge & Cox San Francisco, CA10.6MShares$1.38 Billion0.78% of portfolio
-
Primecap Management CO Pasadena, CA10.4MShares$1.34 Billion1.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX9.06MShares$1.17 Billion0.26% of portfolio
-
Morgan Stanley New York, NY7.56MShares$976 Million0.06% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa7.12MShares$920 Million0.35% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $278B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...